Literature DB >> 27478199

The contribution of mouse models to the understanding of constitutional thrombocytopenia.

Catherine Léon1, Arnaud Dupuis2, Christian Gachet2, François Lanza2.   

Abstract

Constitutional thrombocytopenias result from platelet production abnormalities of hereditary origin. Long misdiagnosed and poorly studied, knowledge about these rare diseases has increased considerably over the last twenty years due to improved technology for the identification of mutations, as well as an improvement in obtaining megakaryocyte culture from patient hematopoietic stem cells. Simultaneously, the manipulation of mouse genes (transgenesis, total or conditional inactivation, introduction of point mutations, random chemical mutagenesis) have helped to generate disease models that have contributed greatly to deciphering patient clinical and laboratory features. Most of the thrombocytopenias for which the mutated genes have been identified now have a murine model counterpart. This review focuses on the contribution that these mouse models have brought to the understanding of hereditary thrombocytopenias with respect to what was known in humans. Animal models have either i) provided novel information on the molecular and cellular pathways that were missing from the patient studies; ii) improved our understanding of the mechanisms of thrombocytopoiesis; iii) been instrumental in structure-function studies of the mutated gene products; and iv) been an invaluable tool as preclinical models to test new drugs or develop gene therapies. At present, the genetic determinants of thrombocytopenia remain unknown in almost half of all cases. Currently available high-speed sequencing techniques will identify new candidate genes, which will in turn allow the generation of murine models to confirm and further study the abnormal phenotype. In a complementary manner, programs of random mutagenesis in mice should also identify new candidate genes involved in thrombocytopenia. Copyright© Ferrata Storti Foundation.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27478199      PMCID: PMC4967568          DOI: 10.3324/haematol.2015.139394

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  118 in total

1.  Non-myeloablative conditioning with busulfan before hematopoietic stem cell transplantation leads to phenotypic correction of murine Bernard-Soulier syndrome.

Authors:  S Kanaji; S A Fahs; J Ware; R R Montgomery; Q Shi
Journal:  J Thromb Haemost       Date:  2014-08-26       Impact factor: 5.824

2.  P-Selectin Sustains Extramedullary Hematopoiesis in the Gata1 low Model of Myelofibrosis.

Authors:  Gerald J Spangrude; Daniel Lewandowski; Fabrizio Martelli; Manuela Marra; Maria Zingariello; Laura Sancillo; Rosa Alba Rana; Anna Rita Migliaccio
Journal:  Stem Cells       Date:  2015-10-23       Impact factor: 6.277

3.  A mutation in the translation initiation codon of Gata-1 disrupts megakaryocyte maturation and causes thrombocytopenia.

Authors:  Ian J Majewski; Donald Metcalf; Lisa A Mielke; Danielle L Krebs; Sarah Ellis; Marina R Carpinelli; Sandra Mifsud; Ladina Di Rago; Jason Corbin; Nicos A Nicola; Douglas J Hilton; Warren S Alexander
Journal:  Proc Natl Acad Sci U S A       Date:  2006-09-11       Impact factor: 11.205

4.  Proplatelet formation deficit and megakaryocyte death contribute to thrombocytopenia in Myh9 knockout mice.

Authors:  A Eckly; J-Y Rinckel; P Laeuffer; J-P Cazenave; F Lanza; C Gachet; C Léon
Journal:  J Thromb Haemost       Date:  2010-10       Impact factor: 5.824

5.  Improvement of migratory defects in a murine model of Wiskott-Aldrich syndrome gene therapy.

Authors:  Michael P Blundell; Gerben Bouma; Yolanda Calle; Gareth E Jones; Christine Kinnon; Adrian J Thrasher
Journal:  Mol Ther       Date:  2008-03-18       Impact factor: 11.454

6.  AML1/Runx1 negatively regulates quiescent hematopoietic stem cells in adult hematopoiesis.

Authors:  Motoshi Ichikawa; Susumu Goyama; Takashi Asai; Masahito Kawazu; Masahiro Nakagawa; Masataka Takeshita; Shigeru Chiba; Seishi Ogawa; Mineo Kurokawa
Journal:  J Immunol       Date:  2008-04-01       Impact factor: 5.422

7.  A model for obesity and gigantism due to disruption of the Ankrd26 gene.

Authors:  Tapan K Bera; Xiu-Fen Liu; Masanori Yamada; Oksana Gavrilova; Eva Mezey; Lino Tessarollo; Miriam Anver; Yoonsoo Hahn; Byungkook Lee; Ira Pastan
Journal:  Proc Natl Acad Sci U S A       Date:  2007-12-27       Impact factor: 11.205

8.  AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis.

Authors:  T Okuda; J van Deursen; S W Hiebert; G Grosveld; J R Downing
Journal:  Cell       Date:  1996-01-26       Impact factor: 41.582

9.  Deficiencies in progenitor cells of multiple hematopoietic lineages and defective megakaryocytopoiesis in mice lacking the thrombopoietic receptor c-Mpl.

Authors:  W S Alexander; A W Roberts; N A Nicola; R Li; D Metcalf
Journal:  Blood       Date:  1996-03-15       Impact factor: 22.113

10.  Cytoskeletal perturbation leads to platelet dysfunction and thrombocytopenia in variant forms of Glanzmann thrombasthenia.

Authors:  Loredana Bury; Emanuela Falcinelli; Davide Chiasserini; Timothy A Springer; Joseph E Italiano; Paolo Gresele
Journal:  Haematologica       Date:  2015-10-09       Impact factor: 9.941

View more
  3 in total

1.  Exploring the Link Between Platelet Numbers and Vascular Homeostasis Across Early and Late Stages of Fibrosis in Hepatitis C.

Authors:  Rabab O Ali; Mi Sun Moon; Elizabeth C Townsend; Kareen Hill; Grace Y Zhang; Alyson Bradshaw; Hannah Guan; Destanee Hamilton; David E Kleiner; Sungyoung Auh; Christopher Koh; Theo Heller
Journal:  Dig Dis Sci       Date:  2019-08-12       Impact factor: 3.199

Review 2.  Genetics of inherited thrombocytopenias.

Authors:  Julia T Warren; Jorge Di Paola
Journal:  Blood       Date:  2022-06-02       Impact factor: 25.476

Review 3.  Rare Genetic Blood Disease Modeling in Zebrafish.

Authors:  Alberto Rissone; Shawn M Burgess
Journal:  Front Genet       Date:  2018-08-31       Impact factor: 4.599

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.